Iacopo Petrini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6105445/publications.pdf

Version: 2024-02-01

86	2,742	218677	189892
papers	citations	26 h-index	50 g-index

91	91	91	4174
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. Cancer Treatment Reviews, 2022, 104, 102340.	7.7	21
2	ED-B-Containing Isoform of Fibronectin in Tumor Microenvironment of Thymomas: A Target for a Theragnostic Approach. Cancers, 2022, 14, 2592.	3.7	8
3	Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing. Genome Biology, 2022, 23, .	8.8	40
4	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. Cancer Immunology, Immunotherapy, 2021, 70, 1667-1678.	4.2	27
5	Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. Molecular Cancer, 2021, 20, 32.	19.2	27
6	Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation. Frontiers in Oncology, 2021, 11, 674604.	2.8	2
7	Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results. Annals of Translational Medicine, 2021, 9, 957-957.	1.7	8
8	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. Pharmacological Research, 2021, 169, 105643.	7.1	13
9	Thymectomy in Myasthenic Patients With Thymoma: Killing Two Birds With One Stone. Annals of Thoracic Surgery, 2021, 112, 1782-1789.	1.3	16
10	Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients. Journal of Thoracic Disease, 2021, 13, 6373-6380.	1.4	1
11	Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clinical Lung Cancer, 2020, 21, 232-237.	2.6	24
12	erbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open, 2020, 5, e000724.	4.5	22
13	Surgical treatment of pleural recurrence of thymoma: is hyperthermic intrathoracic chemotherapy worthwhile?. Interactive Cardiovascular and Thoracic Surgery, 2020, 30, 765-772.	1.1	18
14	Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results. Frontiers in Immunology, 2020, 11, 573156.	4.8	8
15	Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 593831.	2.8	25
16	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. International Journal of Molecular Sciences, 2019, 20, 3951.	4.1	62
17	The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. BMC Cancer, 2019, 19, 410.	2.6	16
18	From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. Lung Cancer, 2019, 131, 78-85.	2.0	42

#	Article	IF	Citations
19	Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment. Pharmacogenomics, 2019, 20, 1255-1257.	1.3	7
20	Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.. Journal of Clinical Oncology, 2019, 37, e14054-e14054.	1.6	0
21	Progression free survival and time to local failure after radiosurgery of pleural metastases in twenty-two patients with thymomas.. Journal of Clinical Oncology, 2019, 37, 8565-8565.	1.6	0
22	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. British Journal of Cancer, 2018, 118, 820-824.	6.4	190
23	The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death and Differentiation, 2018, 25, 1239-1258.	11.2	81
24	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. Cancer Biomarkers, 2018, 21, 731-741.	1.7	16
25	Medical treatment of malignant pleural mesothelioma relapses. Journal of Thoracic Disease, 2018, 10, S333-S341.	1.4	4
26	The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. British Journal of Cancer, 2018, 119, 1252-1258.	6.4	39
27	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). Cancer Treatment Reviews, 2018, 71, 76-87.	7.7	38
28	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. Pharmacogenomics, 2018, 19, 727-740.	1.3	20
29	RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clinical Lung Cancer, 2018, 19, e811-e814.	2.6	15
30	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget, 2018, 9, 6630-6643.	1.8	42
31	Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC.. Journal of Clinical Oncology, 2018, 36, 210-210.	1.6	0
32	Human adult mesangiogenic progenitor cells reveal an early angiogenic potential, which is lost after mesengenic differentiation. Stem Cell Research and Therapy, 2017, 8, 106.	5.5	11
33	Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. Clinical Lung Cancer, 2017, 18, 692-697.	2.6	49
34	THU0308â€...Extensive analysis of T cell receptor gamma (TCRG) gene rearrangements reveals a similar repertoire in eosinophilic granulomatosis with polyangiitis (EGPA) and in hypereosinophilic syndrome (HES). , 2017, , .		0
35	A retrospective analysis of patients (pts) with non-small-cell lung cancer (NSCLC) with uncommon or complex epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors (EGFR-TKIs): clinical features and outcome. Annals of Oncology, 2017, 28, vi56.	1.2	0
36	ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology. Oncotarget, 2017, 8, 4914-4921.	1.8	32

#	Article	IF	Citations
37	Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup. Oncotarget, 2017, 8, 79188-79200.	1.8	5
38	Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment. Oncotarget, 2017, 8, 86056-86065.	1.8	13
39	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget, 2017, 8, 13611-13619.	1.8	81
40	GTF2I Mutations Are Common in Thymic Epithelial Tumors But Not in Hematological Malignancies. , 2017, 37, 5459-5462.		9
41	Growth Factor Content in Human Sera Affects the Isolation of Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow. Frontiers in Cell and Developmental Biology, 2016, 4, 114.	3.7	7
42	Nanotopography Induced Human Bone Marrow Mesangiogenic Progenitor Cells (MPCs) to Mesenchymal Stromal Cells (MSCs) Transition. Frontiers in Cell and Developmental Biology, 2016, 4, 144.	3.7	2
43	The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia. Frontiers in Pharmacology, 2016, 7, 363.	3.5	26
44	Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications. Epigenomics, 2016, 8, 1151-1167.	2.1	8
45	Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. Oncology, 2016, 91, 311-316.	1.9	11
46	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood, 2016, 128, 5697-5697.	1.4	2
47	KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA.. Journal of Clinical Oncology, 2016, 34, e20526-e20526.	1.6	0
48	2372 Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer?. European Journal of Cancer, 2015, 51, S460-S461.	2.8	0
49	Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. Annals of Oncology, 2015, 26, vi99.	1.2	0
50	Realâ€Time <scp>PCR</scp> and Droplet Digital <scp>PCR</scp>: two techniques for detection of the <scp>JAK</scp>2^{V617F} mutation in Philadelphiaâ€negative chronic myeloproliferative neoplasms. International Journal of Laboratory Hematology, 2015, 37, 766-773.	1.3	30
51	Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense?. Annals of Oncology, 2015, 26, vi98.	1.2	0
52	Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. Annals of Oncology, 2015, 26, vi105.	1.2	0
53	149 LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES. Leukemia Research, 2015, 39, S75.	0.8	0
54	Biology of MET: a double life between normal tissue repair and tumor progression. Annals of Translational Medicine, 2015, 3, 82.	1.7	38

#	Article	IF	Citations
55	Are MSCs angiogenic cells? New insights on human nestin-positive bone marrow-derived multipotent cells. Frontiers in Cell and Developmental Biology, 2014, 2, 20.	3.7	51
56	Gtf2I Mutations are Frequent in Thymic Epithelial Tumors. Annals of Oncology, 2014, 25, iv542.	1.2	0
57	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Expert Review of Molecular Diagnostics, 2014, 14, 453-468.	3.1	17
58	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature Genetics, 2014, 46, 844-849.	21.4	208
59	Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report. Journal of Thoracic Oncology, 2014, 9, 414-418.	1.1	33
60	Mutations of epigenetic regulatory genes are common in thymic carcinomas. Scientific Reports, 2014, 4, 7336.	3.3	109
61	Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. Journal of Clinical Oncology, 2014, 32, 11056-11056.	1.6	0
62	Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms. Blood, 2014, 124, 5548-5548.	1.4	0
63	Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for Patients' Risk Stratification. Blood, 2014, 124, 5579-5579.	1.4	0
64	Reproducibility of the WHO classification of thymomas: Practical implications. Lung Cancer, 2013, 79, 236-241.	2.0	37
65	Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors. Clinical Cancer Research, 2013, 19, 1960-1971.	7.0	38
66	Whole Genome and Transcriptome Sequencing of a B3 Thymoma. PLoS ONE, 2013, 8, e60572.	2.5	28
67	NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2012, 7, 744-750.	1.1	18
68	Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 524-533.	7.0	21
69	Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death and Disease, 2012, 3, e351-e351.	6.3	63
70	Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. Journal of Hematology and Oncology, 2012, 5, 53.	17.0	9
71	CD57 and Î³Î´ Tâ€cell receptor expression in nodal metastatic spread of melanoma. European Journal of Clinical Investigation, 2012, 42, 575-576.	3.4	1
72	Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2012, 69, 773-780.	2.3	61

#	Article	IF	Citations
73	Impaired function of gamma-delta lymphocytes in melanoma patients. European Journal of Clinical Investigation, 2011, 41, 1186-1194.	3.4	20
74	Thymic Malignancies: From Clinical Management to Targeted Therapies. Journal of Clinical Oncology, 2011, 29, 4820-4827.	1.6	123
75	Abstract LB-314: Array comparative genomic hybridization of thymic epithelial tumors identifies loss of CDKN2A as a prognostic factor and BCL2 family members as targets for therapy. , 2011, , .		0
76	Array-based comparative genomic hybridization analysis to identify prognostic markers for resected pancreatic cancer.. Journal of Clinical Oncology, 2011, 29, 4097-4097.	1.6	0
77	Expression and Mutational Status of c-kit in Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2010, 5, 1447-1453.	1.1	61
78	Insulinâ€like growth factorâ€1 receptor and phosphorylated AKTâ€serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer, 2010, 116, 4686-4695.	4.1	59
79	MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Nonâ€“Small Cell Lung Carcinoma. Cancer Research, 2010, 70, 8288-8298.	0.9	121
80	Abstract 2995: MicroRNA expression and outcome of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program (IALT-Bio). , 2010, , .		0
81	A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. British Journal of Cancer, 2009, 100, 1720-1724.	6.4	30
82	Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gammaâ€“delta T cells. European Journal of Clinical Investigation, 2009, 39, 813-818.	3.4	23
83	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 2622-2629.	1.6	402
84	Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 7-14.	2.3	15
85	Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. Journal of Clinical Oncology, 2008, 26, 4003-4003.	1.6	21
86	Different Î³/Î´ T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Leukemia Research, 2006, 30, 529-535.	0.8	14